Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC
Status:
Withdrawn
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
A phase II trial evaluating Cabazitaxel in patients with brain metastasis secondary to breast
and non-small-cell lung cancer (NSCLC).
OBJECTIVES:
Primary:
The purpose of this study is to determine if cabazitaxel can induce a reduction in the size
brain metastasis in metastatic HER2-negative breast cancer and NSCLC with brain metastasis
who were not previously treated with whole brain irradiation or require immediate brain
irradiation.
Secondary:
- To determine the effect of cabazitaxel on the time to initiating whole brain irradiation
or radiosurgery
- To determine the effect of cabazitaxel on the time to developing neurological symptoms
- To determine the effect of cabazitaxel on the time to disease progression in the brain
- To determine the effect of cabazitaxel on the time to disease progression outside the
brain. This will be evaluated separately for the breast and NSCLC cohorts To determine
the objective extra-cranial response (if applicable). This will be evaluated separately
in the breast and NSCLC cohorts
- To determine the safety of cabazitaxel